Harvard Health Blog
Read posts from experts at Harvard Health Publishing covering a variety of health topics and perspectives on medical news.
We often report about the psychological toll of mental illness, but while researching a story today I came across a study that documents the economic toll of psychiatric disorders–especially when they are not adequately treated.
Atul Gawande’s piece about end-of-life care in the Aug. 2 issue of The New Yorker is another gem by the surgeon-writer-health policy wonk and staff member at Harvard-affialiated Brigham and Women’s Hospital in Boston.
Fish and shellfish are natural sources of the omega-3 fats that are believed to pay all kinds of health dividends, and there are some good epidemiologic clues that eating fish reduces the likelihood of getting macular degeneration (no guarantee, but you improve the odds).
Being diagnosed with prostate cancer may increase a man’s risk of suicide, but more research is needed to fully evaluate the impact of such a diagnosis on mental health.
A 2010 study of more than 22,500 California men found that being infertile significantly raised the risk of developing aggressive disease.
In our October issue of the Harvard Mental Health Letter, we offer advice about how to manage dental phobia. I’d love to hear from readers of this blog about what techniques they use to cope with their own dental fear. I’ll compile representative replies in a later post.
As for the term “subconscious,” Freud used it interchangeably with “unconscious” at the outset. The words are similarly close but not identical in German (subconscious is das Unterbewusste; unconscious is das Unbewusste).
Three experts from Harvard Medical School discuss radiation therapy, its delivery methods, and treatment modalities. Recent advances in radiation therapy and possible side effects are also explored.
Two studies come to different conclusions about the benefits, leaving patients and their doctors to decide what makes sense.
Many experts believe prostate cancer is the exception to the rule when it comes to screening. In fact, PSA screening may actually do more harm than good. Two studies, one conducted in the U.S. and the other in Europe, were hopefully going to settle the debate over the value of the PSA. While they gave us some answers, we are still a long way from settling the debate.
Genetic biomarkers may help doctors decide whether to perform a biopsy, determine the best treatment, and develop new targeted therapies for prostate cancer.
Renowned radiation oncologist and researcher Anthony D’Amico, M.D., Ph.D. discusses his PSA research and its implications for prostate cancer treatment.
Elliot and Elizabeth Boyd share their experience with a prostate cancer diagnosis, explain their next steps in light of seemingly contradictory test results, and offer advice to those coping with their diagnosis and weighing treatment options.
Two prostate cancer survivors talk about the importance of prostate cancer education among African Americans and other men at high risk.
Ken Gannon talks about his 13 year battle with prostate cancer and his experiences with second-line hormone therapies, investigational drugs, and four clinical trials, one of which nearly killed him.
Patient Ben Hunter explains why he decided to postpone treatment for prostate cancer and the lifestyle changes he made immediately following his diagnosis.
Patient Jeffrey Caruso explains why he decided to pursue active surveillance and under what circumstances he would opt to treat his prostate cancer.
How endorectal MRI helped one couple choose the “best” treatment for prostate cancer.
After talking with numerous medical professionals and asking friends about how they treated their prostate cancers, financial services executive Steve Henley opted to have a robotic-assisted laparoscopic prostatectomy. In this interview, he explains what factors went into that decision.
Study shows that taking both dutasteride (Avodart) and tamsulosin (Flomax) might be more effective at easing symptoms than taking just one.
Given the beneficial effects and the lack of a survival difference, intermittent hormone therapy may be a preferred regimen for men with advanced prostate cancer.
High levels of selenium in the blood are associated with a slightly higher-than-normal risk of aggressive prostate cancer.
A European study finds that mortality is higher among men who pursue hormone therapy for just six months. But the study was conducted in men with relatively large tumors, not small, early-stage tumors, the kind found most often in American men.
According to a 2007 Swedish study, a PSA test done between the ages of 44 and 50 may predict whether or not a man will develop prostate cancer later in life.
